Corvus Pharma Files Proxy Statement
Ticker: CRVS · Form: DEFA14A · Filed: Apr 25, 2025 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | DEFA14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, governance
Related Tickers: CRVS
TL;DR
CRVS proxy statement filed, shareholders vote soon.
AI Summary
Corvus Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on April 25, 2025. This filing is related to the company's proxy materials, likely for an upcoming shareholder meeting. The filing was made with the SEC under the 1934 Act and concerns the company's corporate governance and shareholder voting matters.
Why It Matters
This filing provides shareholders with essential information regarding voting rights and corporate decisions, allowing them to participate in the governance of Corvus Pharmaceuticals.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating any immediate financial or operational risks.
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Registrant
- 0001558370-25-005557 (filing_id) — Accession Number
- 20250425 (date) — Filing Date
FAQ
What type of filing is this?
This is a Definitive Proxy Statement (DEFA14A) filed by Corvus Pharmaceuticals, Inc.
When was this filing made?
The filing was made on April 25, 2025.
What is the company's Central Index Key (CIK)?
The company's CIK is 0001626971.
What is the company's business address?
The business address is 863 Mitten Road, Suite 102, Burlingame, CA 94010.
Under which SEC Act was this filing made?
This filing was made under the Securities Exchange Act of 1934.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 25, 2025 regarding Corvus Pharmaceuticals, Inc. (CRVS).